<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01814423</url>
  </required_header>
  <id_info>
    <org_study_id>2013-CQ</org_study_id>
    <nct_id>NCT01814423</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study of Multi-dose Chloroquine</brief_title>
  <official_title>Pharmacokinetic Study of Multi-dose Chloroquine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bandim Health Project</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bandim Health Project</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chloroquine (CQ) remains an alternative cheap, safe and widely available drug. Our previous&#xD;
      research has shown that double (50 mg/kg) standard dose CQ given in split doses had a 95%&#xD;
      efficacy and was well tolerated and safe. Still, safety could be an issue when the dose of CQ&#xD;
      is increased. Severe adverse events are caused by high peak concentrations of CQ. Using split&#xD;
      doses of CQ avoids high peak concentrations enabling the safe administration of high doses,&#xD;
      however, pharmacokinetic data are lacking.&#xD;
&#xD;
      Children included in the study will be given 50 mg/kg as split doses over 3 days or 70 mg/kg&#xD;
      as split doses over 5 days. Treatment will be observed. Drug concentrations and adverse&#xD;
      events will be monitored. On day 1, children and their mother/guardian will be requested to&#xD;
      stay at the health centre between 9 am and 6 pm.&#xD;
&#xD;
      Fifteen children aged 2-10 years with uncomplicated P. falciparum malaria and fulfilling the&#xD;
      inclusion criteria will be recruited into each study arm.&#xD;
&#xD;
      Following the end of treatment, the children will be seen on the morning of day 7, 14, 21 and&#xD;
      28.&#xD;
&#xD;
      Any child wishing to withdraw during the treatment phase and any child with reparasitaemia&#xD;
      during the follow up will be given rescue treatment with arthemeter-lumefantrine or quinine&#xD;
      according to treatment guidelines in Guinea-Bissau.&#xD;
&#xD;
      Final analysis will include a description of included children, proportions of adverse events&#xD;
      and any serious adverse events, drug concentrations and their relation to adverse events, the&#xD;
      proportion of children withdrawn or lost to follow up, the cumulative PCR corrected and&#xD;
      uncorrected success and failure rates on day 28 and the proportion of early, late clinical&#xD;
      and late parasitological treatment failures.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Chloroquine serum concentration</measure>
    <time_frame>Twice daily during treatment, on day 1 an additional 8 measurements.</time_frame>
    <description>Filterpaper blood samples will be collected in the morning and evening on the days of treatment. On day 1 hourly during daytime.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Parasitemia</measure>
    <time_frame>Twice a day dúring treatment and then weekly until day 28.</time_frame>
    <description>Blood smear for microscopy will be performed in the morning and evening on the days of treatment, and for the 50 mg group on day 3. During follow-uo weekly until day 28.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Haemoglobin level</measure>
    <time_frame>On day 0, 3 and 28.</time_frame>
    <description>The haemoglobin level will be measured on the the specified days.</description>
  </other_outcome>
  <other_outcome>
    <measure>Blood pressure</measure>
    <time_frame>On day 1 and day 28</time_frame>
    <description>Will be measures on day 1 at midday and on day 28.</description>
  </other_outcome>
  <other_outcome>
    <measure>ECG</measure>
    <time_frame>Will be measures on day 1 and on last treatment day.</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Malaria</condition>
  <arm_group>
    <arm_group_label>Chloroquine-base 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chloroquine-base 10 mg/kg twice a day for 2 days and 5 mg/kg twice a day for another day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chloroquine-base 70 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Chloroquine-base 10 mg/kg twice a day for 2 days and 5 mg/kg twice a day for another 3 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chloroquine-base 50 mg</intervention_name>
    <arm_group_label>Chloroquine-base 50 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chloroquine-base 70 mg</intervention_name>
    <arm_group_label>Chloroquine-base 70 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 2 years and &lt; 10 years.&#xD;
&#xD;
          -  Mono-infection with P. falciparum detected by microscopy. Parasitemia of&#xD;
             1.000-100.000/µl asexual forms.&#xD;
&#xD;
          -  Axillary temperature ≥ 37.5 ˚C or a history of fever within 24 hours.&#xD;
&#xD;
          -  Ability to swallow oral medication.&#xD;
&#xD;
          -  Ability and willingness to comply with the study protocol.&#xD;
&#xD;
          -  Informed consent from a parent or guardian&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Signs or symptoms of severe malaria.&#xD;
&#xD;
          -  Presence of general danger signs in children under 5.&#xD;
&#xD;
          -  Persistent vomiting.&#xD;
&#xD;
          -  Presence of severe malnutrition.&#xD;
&#xD;
          -  Any evidence of chronic disease or acute infection other than malaria.&#xD;
&#xD;
          -  Regular medication which may interfere with antimalarial pharmacokinetics.&#xD;
&#xD;
          -  History of hypersensitivity reactions or contraindications to chloroquine.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>9 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Poul-Erik Kofoed, Ph.d</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bandim Health Project</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Projecto de Saúde de Bandim</name>
      <address>
        <city>Bissau</city>
        <zip>1004</zip>
        <country>Guinea-Bissau</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Guinea-Bissau</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <study_first_submitted>March 16, 2013</study_first_submitted>
  <study_first_submitted_qc>March 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2013</study_first_posted>
  <last_update_submitted>March 10, 2014</last_update_submitted>
  <last_update_submitted_qc>March 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Plasmodium falciparum</keyword>
  <keyword>malaria</keyword>
  <keyword>chloroquine</keyword>
  <keyword>pharmacokinetic</keyword>
  <keyword>children</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chloroquine</mesh_term>
    <mesh_term>Chloroquine diphosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

